Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
Adoptive T-Cell Therapy: Ready for Prime Time
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—Chimeric antigen receptor (CAR) T-cell therapy is changing cancer care. In 2010, there were just 3 CAR T-cell clinical trials. As of May 2017, 183 clinical trials are underway, and for the first time, there are more clinical trials in China than in the United States, according to Carl H. June, MD, Director, Translational Research Program, University of Pennsylvania, Philadelphia, at the 2017 ASCO annual meeting. Dr June discussed how this rapidly evolving technology is taking immuno-oncology to the “next level” of precision medicine.
Read Article
ASCO President Lists Progress Made in Cancer, Highlighting Current Priorities
By
Wayne Kuznar
Cancer Care
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—The theme of the 2017 American Society of Clinical Oncology (ASCO) annual meeting was “Making a Difference in Cancer Care With You.” The meeting attracted 38,000 attendees from around the world over 5 days.
Read Article
Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—In the longest follow-up on single-agent nivolumab (Opdivo) to date, 5-year overall survival was 16% in patients with advanced non–small-cell lung cancer (NSCLC) in the updated results of a phase 1b dose-ranging study (CA209-003). This represents a quadrupling of 5-year overall survival with standard platinum doublets, which is approximately 4% for patients with metastatic NSCLC.
Read Article
Letermovir Prophylaxis After Transplant for Cytomegalovirus
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Prophylaxis with letermovir beginning after hematopoietic-cell transplantation (HCT) and lasting through 100 days reduced the risk for clinically significant cytomegalovirus (CMV) infection. Furthermore, letermovir was associated with lower all-cause mortality compared with placebo, reported Francisco M. Marty, MD, Associate Professor of Medicine, Harvard Medical School, Boston, at the 2017 BMT Tandem Meetings.
Read Article
PV-10 Therapy Shows Promise for Hepatic Tumors
By
Walter Alexander
Emerging Therapies
,
Personalized Medicine
June 2017, Vol 8, No 3
Hollywood, FL—A basket study of the oncolytic immunotherapy PV-10 (10% Rose Bengal disodium for injection), which included patients with tumors originating in various locations, showed that data for gastrointestinal lesions were especially encouraging, reported Paul M. Goldfarb, MD, FACS, a surgeon at Oncology Associates of San Diego, CA, at the 2017 Clinical Interventional Oncology annual symposium.
Read Article
Excellent Responses to Atezolizumab in Small Subset of Women with Triple-Negative Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—Preliminary data show excellent and durable responses to atezolizumab (Tecentriq) in 10% of women with triple-negative breast cancer, one of the most aggressive and difficult-to-treat cancers. Of the responders to atezolizumab, 100% were alive at 1 year compared with only 38% of nonresponders. The trick will be to identify which women will respond to immune checkpoint inhibitor therapy. Thus far, no biomarkers for response have been identified.
Read Article
Impact of Elevated Tumor-Infiltrating Lymphocytes Differs Across Breast Cancer Subtypes
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
June 2017, Vol 8, No 3
San Antonio, TX—Concentrations of tumor-infiltrating lymphocytes (TILs) had significant but variable associations with survival in breast cancer, according to 2 large retrospective studies of pathology specimens reported at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Enthusiasm for immunotherapy in the treatment of cancer must be balanced with a healthy respect for the power of T-cell activation. Autoimmunity is recognized as an effect of prolonged T-cell activation via PD-1/PD ligand 1 inhibition. Although immune-related adverse events are generally easily managed, they occasionally can be fatal and therefore should be managed without delay, said Stephanie Andrews, MS, ANP-BC, a hospitalist specializing in medical oncology at Moffitt Cancer Center, Tampa, FL, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference.
Read Article
Immune Stimulant Fails Randomized Test in Platinum-Resistant Ovarian Cancer
By
Charles Bankhead
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
National Harbor, MD—Platinum-resistant ovarian cancer also appeared resistant to the immunotherapeutic effects of the toll-like receptor 8 (TLR8) agonist motolimod as add-on to chemotherapy, according to results of a randomized trial.
Read Article
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab (Keytruda) led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, said lead investigator Yousef Zakharia, MD, Clinical Assistant Professor of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, at the 2017 American Association for Cancer Research meeting.
Read Article
Page 10 of 35
5
6
7
8
9
10
11
12
13
14
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma